.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ayushman Bharat cancer coverage is a cornerstone of India's healthcare strategy, offering a vital lifeline for thousands of oncology patients. Notably, the scheme has provided financial protection for over 68 lakh treatments since its inception in 2018. Consequently, rural and low-income populations have gained access to advanced targeted therapies that were once out of reach. A study in The Lancet highlights that enrollment increases the chance of starting treatment within 30 days by 90%.
Despite these gains, a significant gap remains between current funding and the actual cost of standard care. Specifically, the FinCan study led by Dr. Abhishek Shankar from AIIMS Delhi reveals a substantial annual funding deficit. While the scheme currently allocates approximately Rs 7,700 crore for oncology, the full standard of care requires an estimated Rs 33,000 crore. Therefore, experts advocate for smarter spending to maximize the impact of every rupee. Furthermore, expediting diagnosis and treatment initiation could save Rs 1,500 crore and over 1,500 lives annually.
One major recommendation involves replacing the annual Rs 5 lakh cap with a five-year revolving ceiling of Rs 25 lakh. This reform would allow families to use more funds during high-cost periods, like the initial year of surgery. Additionally, the study supports a Rs 10 lakh top-up for high-stage cancers requiring expensive specialized interventions. Integrating diagnostics into the main scheme is also critical, as they currently represent only 3% of care costs. Lastly, the 2025-26 Union Budget has earmarked funds for 200 new day care cancer centers to further decentralize care.
Q1: How has PM-JAY improved cancer treatment timelines?
Enrolment in AB-PMJAY has increased the likelihood of initiating cancer treatment within 30 days of diagnosis by approximately 90% compared to pre-2018 levels.
Q2: What is the proposed 'revolving ceiling' for cancer care?
The FinCan study suggests a five-year revolving ceiling of Rs 25 lakh per family. This allows patients to use more funds in high-cost years while ensuring continuity of care.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FinCan study highlights the need for expanded Ayushman Bharat cancer coverage, focusing on early diagnosis and revised financial ceilings for patients....
5 months ago
A 2026 meta-analysis evaluates PDE5 inhibitors in advanced ILD with severe gas exchange impairment. While overall mortality was not significantly reduced, a targeted subgroup with pulmonary hypertension showed a 49% risk reduction, underscoring the necessity of precise hemodynamic phenotyping.
Today
A multicentre RCT in China shows that the PAICS AI system significantly boosts sonographer sensitivity in detecting fetal intracranial malformations by 8.7% without compromising specificity, offering promising diagnostic support for prenatal neurosonography.
Today
The Supreme Court questioned FSSAI's phased warning approach, urging single-phase implementation for foods exceeding limits in any nutrient of concern. Backed by ICMR-NIN recommendations, the proposed red hexagonal warnings target added sugar, salt, and fat to combat India's escalating chronic disease epidemic.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
